Lunaphore and Abcam Announce Agreement for Primary Antibody Validation for Use on COMET™, Combining Power of Trusted Antibody Provider With Superior Multiplex Capabilities
6.4.2023 18:04:00 EEST | Business Wire | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (NASDAQ: ABCM), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on Lunaphore’s COMET™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005514/en/
The agreement will enable researchers to use abcam’s antibodies without conjugation directly on the COMET™ platform, with unparalleled scalability and reproducibility. By using validated primary antibodies together with the capabilities of COMET™, researchers can accelerate assay development processes and achieve reliable results. The partnership also aims to address the reproducibility crisis in life sciences by providing trusted tools for multiplex immunofluorescence analysis.
Lunaphore recently expanded its offerings to become the first universal, end-to-end solution for spatial biology research. Lunaphore’s COMET™ is the only high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. It has a wide range of research applications across multiple disciplines and drug development stages, provides walk-away automation, and allows for the generation of highly robust and reproducible hyperplex data with full tissue preservation that answers the growing needs of translational research.
“This collaboration underscores the importance we place on using antibodies from trusted and proven vendors like abcam. We understand how important it is to the research community to use antibodies that they already know and rely on and be able to directly transfer and use them for multiplexing,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “We are very proud to see how customers can already optimize and run new panels in days. Proposing validated abcam antibodies on COMET will help streamline and scale the researchers’ multiplexing capabilities even more.”
“We’re excited to be partnering with Lunaphore to offer the life science community a library of primary antibodies validated for use with Lunaphore’s automated platform for hyperplex immunofluorescence analysis,” said Courtney Nicholson, Vice President Business Development at abcam. “Spatial biology is truly revolutionizing our understanding of human health and disease, and we are pleased to be working together with Lunaphore to support researchers with the tools they need to further advance this promising new field.”
Lunaphore and abcam will present novel data together in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, highlighting shared research:
Automated multiplex immunofluorescence enables single cell analysis of tumor stroma
Poster #: 4616, Section 4
Date and time: April 18, 1:30 pm – 5:00 pm EST
Speaker: Dr. François Rivest, Application Development Team Leader, Lunaphore
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About abcam
At abcam, we believe that the scientific community goes further, faster, when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications.
We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.
To find out more, visit us at www.abcam.com and corporate.abcam.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005514/en/
Contact information
For further information contact:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Abcam Corporate Communications
Email : external.comms@abcam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 09:00:00 EEST | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in children and adolescents with neurological conditions, including CP. This condition is associated with muscle tightness that can severely restrict physical movement, daily functioning, and personal autonomy. Among children and youth, CP stands as a primary driver of this symptom and remains the most prevalent childhood motor disability,
Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 09:00:00 EEST | Press release
The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives that can improve care for people living with haemoglobinopathies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916107487/en/ Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. Avanzanite enabled the establishment of the Network in recognition of both the considerable expertise that already exists across the Mediterranean and the persistent gaps that remain in access to specialist care, sustainable blood supplies, treatment advances and evidence-based inn
IKI Advances Promotional Forecast Accuracy by More Than 10 Points With SymphonyAI17.9.2026 08:03:00 EEST | Press release
SymphonyAI, a global leader in Vertical AI, today announced that IKI, one of Lithuania's largest grocery retailers, is implementing SymphonyAI's Promotional Evaluation and Promotional Planning solutions across its network of 250 stores, as part of its strategy to strengthen data-driven promotional planning. IKI continuously evaluates opportunities to strengthen its category management and promotional planning capabilities. As promotional programs become increasingly sophisticated, the retailer has invested in advanced analytics and AI-driven forecasting to support data-driven decision making across its business. In its initial work with SymphonyAI across select categories, IKI has seen promotional forecast accuracy improve by more than 10 percentage points, along with a reduction in stock-outs during promotional periods. "At IKI, we are constantly looking for innovative ways to strengthen our decision-making with better data and technology," said Klavs Berzins, Head of Category Managem
Lattice Expands Secure Control FPGA Leadership with New Lattice Mach-N2 Family17.9.2026 05:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced Lattice Mach™-N2 FPGA family, extending its long-running secure control FPGA leadership with new devices purpose-built for system control and security in modern infrastructure. Built on the Lattice Nexus™ 2 small FPGA platform, Mach-N2 combines integrated flash, a hardware Root of Trust, and CNSA 2.0-compliant post-quantum cryptography (PQC) with crypto agility for trusted, always-on system control and security across next-generation systems. "The demands on system control and security are accelerating as post-quantum mandates take hold, and customers building long-lifecycle infrastructure seek solutions that will help them design with today and tomorrow’s security needs in mind," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Mach-N2 represents a significant step forward in logic density and bandwidth while adding the most complete post-qua
Lattice Advances FPGA Design with New Leadership AI-Driven Development Tool, Lattice Prompt17.9.2026 05:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today introduced a new leadership AI-powered FPGA development tool for small and mid-range FPGAs that redefines how FPGA developers work across the full design flow. Lattice Prompt pairs with AI agentic tools developers already use, combining them with Lattice design tools, knowledge base, and documentation to turn natural language inputs into validated responses, dramatically accelerating FPGA development while optimizing design performance and capability. "Accelerating time-to-market demands and rising design complexity are putting mounting pressure on FPGA developers to do more with every design cycle," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Lattice Prompt gives developers AI-assisted access to the full design flow, grounded in Lattice's validated knowledge, so they can focus on what matters most: building differentiated systems." Lattice Prompt:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom